BioVaxys Technology (FRA:5LB0) Issuance of Debt: €0.00 Mil (TTM As of Jul. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is BioVaxys Technology Issuance of Debt?

BioVaxys Technology FRA:5LB0 Issuance of Debt is €0.00 Mil as of Jul. 2025.

BioVaxys Technology's Issuance of Debt for the three months ended in Jul. 2025 was €0.00 Mil.

BioVaxys Technology's Issuance of Debt for the trailing twelve months (TTM) ended in Jul. 2025 was €0.00 Mil.

BioVaxys Technology Issuance of Debt Related Terms

BioVaxys Technology Issuance of Debt Historical Data

* Premium members only.

The historical data trend for BioVaxys Technology's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVaxys Technology Issuance of Debt Chart

BioVaxys Technology Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24
Issuance of Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

BioVaxys Technology Quarterly Data
Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.00 0.00 0.00 0.00

BioVaxys Technology Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Jul. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of €0.00 Mil mean?
BioVaxys Technology (FRA:5LB0) has a Issuance of Debt of €0.00 Mil as of Jul. 2025. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on BioVaxys Technology and its competitors.
Is BioVaxys Technology's Issuance of Debt too high?
BioVaxys Technology's current Issuance of Debt is €0.00 Mil.
How does BioVaxys Technology's Issuance of Debt compare to BPTH and AZTR?
BioVaxys Technology's Issuance of Debt of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Biotechnology company?
A good Issuance of Debt depends on the Biotechnology industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on BioVaxys Technology and its competitors. BioVaxys Technology's current Issuance of Debt is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVaxys Technology stock overvalued right now?
BioVaxys Technology (FRA:5LB0) has a current Issuance of Debt of €0.00 Mil. The current Issuance of Debt is €0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For BioVaxys Technology (FRA:5LB0), the current Issuance of Debt is €0.00 Mil as of Jul. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVaxys Technology Business Description

Other Exchanges BVAXF:USABIOV:Canada
Address 595 Howe Street, Suite 303, Vancouver, BC, CAN, V6C 2T5
BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.